Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. (KMDA) is a leading biopharmaceutical company that specializes in plasma-derived protein therapeutics, targeting orphan indications. Utilizing its proprietary platform technology, Kamada excels in the extraction and purification of proteins from human plasma, producing highly-purified, liquid forms of alpha-1 antitrypsin (AAT) and other plasma-derived proteins. AAT is recognized for its immunomodulatory, anti-inflammatory, tissue-protective, and antimicrobial properties.
One of Kamada's flagship products is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration (FDA). Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada offers a diverse product portfolio, including nine other pharmaceutical products distributed globally.
Kamada's robust late-stage product pipeline underscores its commitment to innovation in the specialty therapeutics market. The company operates through two primary segments: the Proprietary Products segment and the Distribution segment, with the majority of revenue derived from the Proprietary Products segment. Kamada's product categories encompass lung diseases, vaccines, hemophilia, immunoglobulins, critical care, and diagnostics.
Recently, Kamada announced a significant development in its strategic partnership with Kedrion Biopharma. The companies have executed a binding memorandum of understanding for an 8-year extension of the KEDRAB® US distribution agreement, starting January 2024. This agreement includes potential expansion of Kedrion's distribution of KEDRAB® beyond the U.S. and collaboration on expanding Kedrion products' distribution in Israel.
KEDRAB® is a Human Rabies Immune Globulin (HRIG) used for passive, transient post-exposure prophylaxis (PEP) of rabies infection, approved by the FDA in August 2017. The agreement signifies a significant milestone for Kamada, maximizing the future growth and value potential of this important product. Kamada continues to prioritize patient care and remains a pivotal player in the plasma-derived therapies sector.
Kamada Ltd. (NASDAQ: KMDA) reported its full-year 2022 financial results, achieving total revenues of $129.3 million and EBITDA of $17.8 million, a 25% increase year-over-year. The company has transitioned from reliance on GLASSIA® sales to a diversified portfolio with six FDA-approved products. Operating cash flow reached $28.6 million, improving the cash position to $34.3 million. For 2023, Kamada projects revenues between $138 million and $146 million and EBITDA of $22 million to $26 million, signaling continued growth driven by strong product demand and expansion in various markets.
Kamada Ltd. reported fiscal year 2022 revenues of $129.3 million, a 25% increase from 2021, with EBITDA of $17.8 million, reflecting a 3x increase year-over-year. The fourth quarter alone saw revenues of $45.4 million, up 44% compared to the previous year. The company forecasts fiscal year 2023 revenues between $138 million and $146 million, representing anticipated growth. Key drivers include sales from CYTOGAM®, KEDRAB®, and GLASSIA® royalties. Kamada also achieved a record operating cash flow of $28.6 million in 2022, enhancing its cash position to $34.3 million.
Kamada Ltd. (NASDAQ: KMDA), a biopharmaceutical company focusing on rare diseases, will announce its financial results for Q4 and the full year ending December 31, 2022, on March 15, 2023, before U.S. market open. A conference call will be held the same day at 8:30 AM ET to discuss the results. Investors can participate by calling specific numbers or via a live webcast. Kamada's portfolio includes six FDA-approved plasma-derived products and a notable investigational product for AAT deficiency currently in a pivotal Phase 3 trial. The company aims to drive growth through its commercial strategies and R&D advancements.
Kamada Ltd. (NASDAQ: KMDA) announced it has submitted an application to the FDA to manufacture CYTOGAM® at its Israeli facility, expecting approval by mid-2023. This marks the completion of the technology transfer from CSL Behring. CYTOGAM is crucial for preventing cytomegalovirus disease post-transplantation and has the highest sales among Kamada's acquired IgG products, with gross margins exceeding 50%. The company plans to initiate commercial manufacturing in the second half of 2023, leveraging its operational capabilities for increased efficiency.
FAQ
What is the current stock price of Kamada (KMDA)?
What is the market cap of Kamada (KMDA)?
What does Kamada Ltd. specialize in?
What is Kamada's flagship product?
Who are Kamada's strategic partners?
What are the main product categories of Kamada?
What recent agreement has Kamada announced?
What is KEDRAB®?
How does Kamada derive its majority of revenue?
What are the key properties of alpha-1 antitrypsin (AAT)?
Which markets does Kamada distribute its pharmaceutical products?
What is the significance of Kamada's recent agreement with Kedrion Biopharma?
